{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:46:41Z","timestamp":1791726401894,"version":"4.3.4"},"reference-count":67,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The therapeutic outcomes of clinical trials for incorporating anti-CD38 monoclonal antibodies (including isatuximab and daratumumab) into the bortezomib\/lenalidomide\/dexamethasone (VRd) triplet therapy backbone as the first-line treatment for newly diagnosed multiple myeloma (NDMM) have demonstrated significant improved efficacies. From a safety perspective, the addition of anti-CD38 monoclonal antibodies into the triplet therapies did not raise additional safety concerns. Based on the promising results, the National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2025 had updated the quadruplet therapy incorporating anti-CD38 monoclonal antibodies with VRd-based therapies as the primary therapy for both transplantation-eligible and transplantation-ineligible NDMM patients. Thus, a panel of experts in hematology and oncology with extensive experience in the treatment of NDMM was convened in 2024 to develop consensus recommendations based on recent evidence from pivotal clinical trials and real-world practices, providing clear guidance for optimizing treatment strategies in both transplantation-eligible and transplantation-ineligible patients. The main topics identified for discussion and recommendation were: (i) the benefits and indications for quadruplet therapy for NDMM; (ii) the optimization of quadruplet therapy strategies; (iii) the management and monitoring of potential adverse events for quadruplet therapy, and (iv) the impact of quadruplet regimens on tandem stem cell transplantation and maintenance treatment. Recommendations were then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including \ufb01ndings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.<\/jats:p>","DOI":"10.46989\/001c.133682","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:35:26Z","timestamp":1744364126000},"source":"Crossref","is-referenced-by-count":5,"title":["Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group"],"prefix":"10.46989","volume":"7","author":[{"given":"Wenming","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital Zhejiang University, China","department":["School of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James CS","family":"Chim","sequence":"additional","affiliation":[{"name":"University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/025yypj46","id-type":"ROR","asserted-by":"publisher"}],"name":"National University Cancer Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"Shanghai Changzheng Hospital, China","department":["Myeloma & Lymphoma Center"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Soochow University, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[{"name":"Aichi Medical University, Japan","department":["Division of Hematology, Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[{"name":"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China","department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Shang-Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Ptushkin","sequence":"additional","affiliation":[{"name":"Botkin Moscow City Clinical Hospital, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Semenova","sequence":"additional","affiliation":[{"name":"Russian Cancer Research Center named after N.N. Blokhin RAMS, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[{"name":"Nerima Hikarigaoka Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Siu Ming","family":"Wong","sequence":"additional","affiliation":[{"name":"Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR","department":["Sir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"7650","key":"ref1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"G. H., et al. Guyatt","year":"2008","journal-title":"Bmj"},{"issue":"6","key":"ref2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"MaV., et al. Mateos","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"10218","key":"ref3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"M. V., et al. Mateos","year":"2020","journal-title":"Lancet"},{"issue":"Supplement 1","key":"ref4","doi-asserted-by":"publisher","first-page":"10157","DOI":"10.1182\/blood-2022-163347","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study","volume":"140","author":"M.-V., et al. Mateos","year":"2022","journal-title":"Blood"},{"issue":"7","key":"ref5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"E. M. Ocio","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"H., et al. Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","author":"X., et al. Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"15","key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS)","volume":"37","author":"Sonja Zweegman","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"ref9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"H. I.","year":"2022"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"L. B., et al. Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10068","key":"ref11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"B. G. M., et al. Durie","year":"2017","journal-title":"The Lancet"},{"issue":"10192","key":"ref12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"P., et al. Moreau","year":"2019","journal-title":"The Lancet"},{"issue":"10214","key":"ref13","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"M., et al. Attal","year":"2019","journal-title":"The Lancet"},{"issue":"10292","key":"ref14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"P., et al. Moreau","year":"2021","journal-title":"The Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Francesca, et al. Gay","year":"2023","journal-title":"Blood"},{"issue":"4","key":"ref16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"P., et al. Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"ref17","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"P. M., et al. Voorhees","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"11","key":"ref18","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"L. J., et al. Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"ref19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","article-title":"Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk","volume":"14","author":"N. S., et al. Callander","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"ref20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2022017635","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"T., et al. Facon","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"S2","key":"ref21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.HS9.0000936164.84357.ed","article-title":"P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY","volume":"7","author":"K., et al. Weisel","year":"2023","journal-title":"HemaSphere"},{"issue":"5","key":"ref22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"B. G. M., et al. Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"T., et al. Facon","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"ref24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How I treat multiple myeloma in geriatric patients","volume":"143","author":"T. Facon","year":"2024","journal-title":"Blood"},{"issue":"8","key":"ref25","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"X., et al. Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"ref26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"A. S., et al. Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"13","key":"ref27","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"A., et al. Palumbo","year":"2015","journal-title":"Blood"},{"issue":"2","key":"ref28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.36000\/HBT.OH.2024.20.151","article-title":"Assessment and Treatment of Elderly Patients with Multiple Myeloma","volume":"20","author":"C. de Ramon Ortiz","year":"2024","journal-title":"healthbook TIMES Onco Hema"},{"issue":"7","key":"ref29","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"M. A., et al. Dimopoulos","year":"2023","journal-title":"The Lancet Oncology"},{"issue":"5","key":"ref30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/nep.12052","article-title":"KHA-CARI Guideline: Early chronic kidney disease: Detection, prevention and management","volume":"18","author":"D. W., et al. Johnson","year":"2013","journal-title":"Nephrology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","author":"S. Z., et al. Usmani","year":"2025","journal-title":"Nature Medicine"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"R., et al. Fonseca","year":"2020","journal-title":"BMC Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/cmar.S105163","article-title":"Update on the optimal use of bortezomib in the treatment of multiple myeloma","volume":"9","author":"M. Mohan","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"17","key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16172938","article-title":"Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naive, Multiple Myeloma","volume":"16","author":"B., et al. Paul","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"ref35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","article-title":"Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?","volume":"97","author":"X., et al. Leleu","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"A., et al. Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1282300","DOI":"10.3389\/fonc.2024.1282300","article-title":"Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma","volume":"14","author":"C., et al. Geraldes","year":"2024","journal-title":"Front Oncol"},{"issue":"2","key":"ref38","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"N. S., et al. Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1002\/ajh.26766","article-title":"Prevention of infections including vaccination strategies in multiple myeloma","volume":"98 Suppl 2","author":"H. Ludwig","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"ref40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajh.22260","article-title":"Drug interaction between lenalidomide and itraconazole","volume":"87","author":"N., et al. Takahashi","year":"2012","journal-title":"Am J Hematol"},{"issue":"1","key":"ref41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"H., et al. Ludwig","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"ref42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"J. L., et al. Zamorano","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"J., et al. El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","author":"T., et al. Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"ref45","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network","volume":"32","author":"H., et al. Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines","volume":"21","author":"D. Bovelli","year":"2010","journal-title":"Annals of Oncology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)","volume":"24","author":"L., et al. Drgona","year":"2018","journal-title":"Clinical Microbiology and Infection"},{"issue":"38","key":"ref48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/EDBK_205443","article-title":"Practical Considerations for Antibodies in Myeloma","author":"J. P., et al. Laubach","year":"2018","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"3","key":"ref49","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host","volume":"58","author":"L. G., et al. Rubin","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"14","key":"ref50","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"J., et al. Martinez-Lopez","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"ref51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"I., et al. Goicoechea","year":"2021","journal-title":"Blood"},{"issue":"23","key":"ref52","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"N. C., et al. Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"20","key":"ref53","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"C., et al. Touzeau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"ref54","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/hematology.2022000356","article-title":"The first relapse in multiple myeloma: how to pick the next best thing","volume":"2022","author":"S. Devarakonda","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"ref55","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"P. M., et al. Voorhees","year":"2020","journal-title":"Blood"},{"issue":"7","key":"ref56","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.bbmt.2018.01.035","article-title":"Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"24","author":"L., et al. Garderet","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"ref57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"W. I., et al. Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"ref58","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1158\/2767-9764.Crc-23-0185","article-title":"Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment","volume":"3","author":"J., et al. Liu","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"5","key":"ref59","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/ejh.13497","article-title":"Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment","volume":"105","author":"C. A., et al. Uyl-de Groot","year":"2020","journal-title":"Eur J Haematol"},{"issue":"13","key":"ref60","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","article-title":"Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM","volume":"2","author":"S., et al. Jagannath","year":"2018","journal-title":"Blood Adv"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","author":"A. Z., et al. Badros","year":"2024","journal-title":"Blood"},{"issue":"8","key":"ref62","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"P., et al. Moreau","year":"2024","journal-title":"The Lancet Oncology"},{"issue":"11","key":"ref63","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.clml.2023.07.001","article-title":"Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma","volume":"23","author":"S., et al. Lonial","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"ref64","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration","volume":"27","author":"K. C., et al. Anderson","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"ref65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis","volume":"3","author":"N. C., et al. Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7001","key":"ref66","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"J. Jones","year":"1995","journal-title":"Bmj"},{"issue":"9","key":"ref67","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2105\/ajph.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"A., et al. Fink","year":"1984","journal-title":"Am J Public Health"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/133682-consensus-guidelines-and-recommendations-for-the-cd38-monoclonal-antibody-based-quadruplet-therapy-and-management-in-clinical-practice-for-newly-diagn","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:17:09Z","timestamp":1791724629000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/133682-consensus-guidelines-and-recommendations-for-the-cd38-monoclonal-antibody-based-quadruplet-therapy-and-management-in-clinical-practice-for-newly-diagn"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.133682","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}